Table 4.
Subgroup analysis of the primary outcome
| Sofosbuvir/daclatasvir (N = 541), n/n (%) | Control (N = 542), n/n (%) | P | |
|---|---|---|---|
| Men | 220/291 (76) | 224/294 (76) | 0.962 |
| Women | 185/250 (78) | 187/248 (75) | 0.716 |
| Patients ≥60 years old | 170/248 (69) | 184/266 (69) | 0.891 |
| Patients <60 years old | 245/293 (84) | 227/276 (82) | 0.783 |
| Any comorbiditya | 215/285 (75) | 203/279 (73) | 0.469 |
| No comorbidity | 200/256 (78) | 208/263 (79) | 0.6474 |
| Days since symptom onset >4 days | 320/422 (76) | 321/422 (76) | 0.936 |
| Days since symptom onset ≤4 days | 95/119 (80) | 90/120 (75) | 0.372 |
| Days since symptom onset >8 days | 109/140 (78) | 121/148 (82) | 0.443 |
| Days since symptom onset ≤8 days | 306/401 (76) | 290/394 (74) | 0.473 |
| Patients with O2 saturation >90% at baseline | 214/254 (84) | 215/257 (84) | 0.984 |
| Patients with O2 saturation ≤90% at baseline | 201/287 (70) | 196/285 (69) | 0.705 |
| PCR positive at baseline | 326/430 (76) | 315/426 (74) | 0.529 |
| PCR negative at baseline | 89/111 (80) | 96/116 (83) | 0.444 |
| Taking dexamethasone | 220/298 (74) | 184/272 (68) | 0.105 |
| Not taking dexamethasone | 195/243 (80) | 227/270 (84) | 0.257 |
P value calculated using χ2 test.
a
Any comorbidity defined as those with any of hypertension, diabetes, ischaemic heart disease, COPD or asthma.